In cancer research, discovering a new protein that plays a role in cancer is like finding a key and a treasure map: follow the clues and eventually there could be a big reward. At least that’s the hope from a new study published in the journal Nature that discovered a novel protein called ceramide-1 phosphate transport protein (CPTP) – a finding that could eventually lead to the development of new drugs to treat a variety of cancers and other conditions involving inflammation and thrombosis, or blood clotting.
The inpatient bone marrow transplant (BMT) unit at VCU Massey Cancer Center is the first of its kind in the nation to earn the American Association of Critical-Care Nurses (AACN) Beacon Award for Excellence. A BMT is a procedure that replaces damaged or destroyed bone marrow with healthy bone marrow stem cells in the treatment of blood cancers like leukemia and lymphoma and other blood and immune disorders. The AACN Beacon Award for Excellence recognizes individual units that distinguish themselves by improving every facet of patient care.
Scientists from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have provided evidence from preclinical experiments that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression. The study, published in the journal Clinical Cancer Research, was a collaborative effort between Paul B. Fisher, M.Ph., Ph.D., who originally discovered the mda-9/syntenin gene, and Santanu Dasgupta, Ph.D., an expert in bladder cancer research.
A new hub for cancer research known as the Massey Research Pavilion opened in April 2013 in the VCU School of Medicine’s McGlothlin Medical Education Center, a new 12-story, 200,000-square-foot, state-of-the-art building. The Massey Research Pavilion—located on floors 11 and 12—provides 27,000-square-feet of dedicated space for VCU Massey Cancer Center’s clinical trials research, cancer prevention and control research and Division of Hematology, Oncology and Palliative Care chair, Steven Grossman, M.D., Ph.D., and his administrators. Each floor is appointed with a suite of research offices and conference rooms.
Khalid Matin, M.D., F.A.C.P., has been appointed medical director of community oncology and clinical research affiliations at VCU Massey Cancer Center and an associate professor in the Division of Hematology, Oncology and Palliative Care, Department of Internal Medicine, at the VCU School of Medicine, effective July 15, 2013.